keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer neuropathy

keyword
https://www.readbyqxmd.com/read/29898756/ndrg1-regulates-neutral-lipid-metabolism-in-breast-cancer-cells
#1
Christopher J Sevinsky, Faiza Khan, Leila Kokabee, Anza Darehshouri, Krishna Rao Maddipati, Douglas S Conklin
BACKGROUND: Altered lipid metabolism is an emerging hallmark of aggressive breast cancers. The N-myc downstream regulated gene (NDRG1) gene plays a critical role in peripheral nervous system myelination, as inactivating mutations cause severe demyelinating neuropathy. In breast cancer, elevated NDRG1 expression has been linked to clinical outcomes, but its functional role in breast cancer physiology has remained unclear. METHODS: A meta-analysis of NDRG1 expression in multiple large publicly available genomic databases was conducted...
June 14, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29895438/phase-2-study-of-dose-dense-doxorubicin-and-cyclophosphamide-followed-by-eribulin-mesylate-with-or-without-prophylactic-growth-factor-for-adjuvant-treatment-of-early-stage-human-epidermal-growth-factor-receptor-2-negative-breast-cancer
#2
Karen A Cadoo, Peter A Kaufman, Andrew D Seidman, Cassandra Chang, Dongyuan Xing, Tiffany A Traina
BACKGROUND: Eribulin has significantly improved overall survival for patients with metastatic breast cancer who received ≥ 2 prior chemotherapy regimens for advanced disease. This trial assessed eribulin as adjuvant therapy for patients with early-stage breast cancer. PATIENTS AND METHODS: Patients with human epidermal growth factor receptor 2-negative, stage I to III breast cancer received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 provided intravenously on day 1 of each 14-day cycle for 4 cycles, with pegfilgrastim on day 2, followed by 4 cycles of eribulin mesylate 1...
April 7, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29889605/integrative-therapies-during-and-after-breast-cancer-treatment-asco-endorsement-of-the-sio-clinical-practice-guideline
#3
Gary H Lyman, Heather Greenlee, Kari Bohlke, Ting Bao, Angela M DeMichele, Gary E Deng, Judith M Fouladbakhsh, Brigitte Gil, Dawn L Hershman, Sami Mansfield, Dawn M Mussallem, Karen M Mustian, Erin Price, Susan Rafte, Lorenzo Cohen
Purpose The Society for Integrative Oncology (SIO) produced an evidence-based guideline on use of integrative therapies during and after breast cancer treatment that was determined to be relevant to the American Society of Clinical Oncology (ASCO) membership. ASCO considered the guideline for endorsement. Methods The SIO guideline addressed the use of integrative therapies for the management of symptoms and adverse effects, such as anxiety and stress, mood disorders, fatigue, quality of life, chemotherapy-induced nausea and vomiting, lymphedema, chemotherapy-induced peripheral neuropathy, pain, and sleep disturbance...
June 11, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29887785/physical-activity-exercise-and-breast-cancer-what-is-the-evidence-for-rehabilitation-aftercare-and-survival-a-review
#4
REVIEW
Petra Wirtz, Freerk T Baumann
The current scientific field of exercise interventions in breast cancer is very large. Rehabilitation focuses on restoring or improving quality of life and thus on independence and participation in life. Hence, it is important to investigate exercise interventions in the setting of rehabilitation and aftercare. It is also necessary to determine the influence of physical activity or exercise therapy on the prevention of recurrence and mortality as well as on certain side effects of the disease and its medical treatment in rehabilitation...
April 2018: Breast Care
https://www.readbyqxmd.com/read/29873695/platinum-based-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer-a-systematic-review-and-meta-analysis
#5
F Poggio, M Bruzzone, M Ceppi, N F Pondé, G La Valle, L Del Mastro, E de Azambuja, M Lambertini
Background: The role of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients is highly controversial and it is not endorsed by current guidelines. Our meta-analysis aimed to better elucidate its activity, efficacy and safety. Material and methods: A systematic search of Medline, Web of Science and conferences proceedings up to 30 October 2017 was carried out to identify randomized controlled trials (RCTs) investigating platinum-based versus platinum-free neoadjuvant chemotherapy in TNBC patients...
June 4, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29864986/chronic-neuropathic-pain-following-oxaliplatin-and-docetaxel-a-5-year-follow-up-questionnaire-study
#6
K J Bennedsgaard, L Ventzel, A B Jensen, A R Jensen, H Tankisi, N B Finnerup
Background Adjuvant chemotherapy with docetaxel and oxaliplatin increases survival in patients with high-risk breast and colorectal cancer, respectively, but may induce acute and chronic neurotoxicity. This study is a 5-year follow-up of chronic chemotherapy-induced peripheral neuropathy (CIPN). Methods In 2011-2012, 74 patients with high-risk colorectal cancer and 100 patients with high-risk breast cancer answered a questionnaire before, during and one year after receiving adjuvant chemotherapy with oxaliplatin and docetaxel, respectively...
December 29, 2017: Scandinavian Journal of Pain
https://www.readbyqxmd.com/read/29746899/ncs-1-is-a-regulator-of-calcium-signaling-in-health-and-disease
#7
REVIEW
Göran R Boeckel, Barbara E Ehrlich
Neuronal Calcium Sensor-1 (NCS-1) is a highly conserved calcium binding protein which contributes to the maintenance of intracellular calcium homeostasis and regulation of calcium-dependent signaling pathways. It is involved in a variety of physiological cell functions, including exocytosis, regulation of calcium permeable channels, neuroplasticity and response to neuronal damage. Over the past 30 years, continuing investigation of cellular functions of NCS-1 and associated disease states have highlighted its function in the pathophysiology of several disorders and as a therapeutic target...
May 7, 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29705914/a-longitudinal-study-of-painless-and-painful-intercostobrachial-neuropathy-after-breast-cancer-surgery
#8
S La Cesa, P Sammartino, C Mollica, G Cascialli, G Cruccu, A Truini, M Framarino-Dei-Malatesta
Intercostobrachial neuropathy, often resulting in neuropathic pain, is a common complication of breast cancer surgery. In this 1-year longitudinal study, we aimed at seeking information on the frequency, clinical features, and course of painless and painful intercostobrachial neuropathy. We enrolled 40 women previously undergoing breast cancer surgery. In these patients, we collected, at 3, 6 and 12 months after surgery, clinical and quantitative sensory testing (QST) variables to diagnose intercostobrachial neuropathy, DN4 questionnaire to identify neuropathic pain, Neuropathic Pain Symptom Inventory to assess the different neuropathic pain symptoms, the Beck Depression Inventory to assess depressive symptoms, and SF36 to assess quality of life and Patient Global Impression of Change...
April 29, 2018: Neurological Sciences
https://www.readbyqxmd.com/read/29703818/paclitaxel-plasma-concentration-after-the-first-infusion-predicts-treatment-limiting-peripheral-neuropathy
#9
Daniel L Hertz, Kelley M Kidwell, Kiran Vangipuram, Feng Li, Manjunath P Pai, Monika Burness, Jennifer J Griggs, Anne F Schott, Catherine Van Poznak, Daniel F Hayes, Ellen Ml Smith, N Lynn Henry
PURPOSE: Paclitaxel exposure, specifically the maximum concentration (Cmax) and amount of time the concentration remains above 0.05 µM (Tc>0.05), have been associated with the occurrence of paclitaxel-induced peripheral neuropathy (PN). The objective of this study was to validate the relationship between paclitaxel exposure and PN.  Experimental Design: Patients with breast cancer receiving paclitaxel 80 mg/m2 x 12 weekly doses were enrolled in an observational clinical study (NCT02338115)...
April 27, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29696771/risk-factors-for-the-development-of-paclitaxel-induced-neuropathy-in-breast-cancer-patients
#10
Jetter Robertson, Jeffrey Raizer, James S Hodges, William Gradishar, Jeffrey A Allen
No abstract text is available yet for this article.
April 25, 2018: Journal of the Peripheral Nervous System: JPNS
https://www.readbyqxmd.com/read/29681015/cold-therapy-to-prevent-paclitaxel-induced-peripheral-neuropathy
#11
Claire Griffiths, Nancy Kwon, Jennifer L Beaumont, Judith A Paice
PURPOSE: This case-control study was designed to assess the efficacy of cryotherapy to prevent paclitaxel-induced painful peripheral neuropathy in women with breast cancer. METHODS: Participants served as their own paired control, with randomization of the cooled glove/sock to either the dominant or the non-dominant hand/foot, worn for 15 min prior to, during, and 15 min after completion of the paclitaxel infusion. Outcome measures included the Neuropathic Pain Symptom Inventory, the Brief Pain Inventory, and quantitative sensory testing...
April 21, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29680193/phase-ii-study-of-paclitaxel-and-dasatinib-in-metastatic-breast-cancer
#12
Patrick G Morris, Selene Rota, Karen Cadoo, Stephen Zamora, Sujata Patil, Gabriella D'Andrea, Theresa Gilewski, Jacqueline Bromberg, Chau Dang, Maura Dickler, Shanu Modi, Andrew D Seidman, Nancy Sklarin, Larry Norton, Clifford A Hudis, Monica N Fornier
BACKGROUND: Overexpression and activation of tyrosine kinase Src has been linked to breast carcinogenesis and bone metastases. We showed the feasibility of combining the SRC inhibitor dasatinib with weekly paclitaxel in patients with metastatic breast cancer (MBC) and herein report the subsequent phase II trial. PATIENTS AND METHODS: Patients had received ≤ 2 chemotherapy regimens for measurable, HER2-negative MBC. Patients received paclitaxel and dasatinib (120 mg daily) and were assessed according to Response Evaluation Criteria in Solid Tumors for overall response rate (ORR), the primary end point...
March 15, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29602320/pre-treatment-anxiety-is-associated-with-persistent-chemotherapy-induced-peripheral-neuropathy-in-women-treated-with-neoadjuvant-chemotherapy-for-breast-cancer
#13
Kwang-Min Lee, Dooyoung Jung, Heesung Hwang, Kyung-Lak Son, Tae-Yong Kim, Seock-Ah Im, Kyung-Hun Lee, Bong-Jin Hahm
OBJECTIVE: Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent adverse reaction caused by chemotherapeutic agents, especially the taxanes. CIPN can persist from months to years after completion of chemotherapy, decreasing quality of life for cancer survivors. The aim of this study was to explore the incidence and risk factors of persistent CIPN among women with breast cancer receiving neoadjuvant chemotherapy. METHODS: In this prospective study, we recruited women with breast cancer receiving neoadjuvant chemotherapy, including four cycles of docetaxel...
May 2018: Journal of Psychosomatic Research
https://www.readbyqxmd.com/read/29587605/chondritis-of-the-ear-after-docetaxel-carboplatin-chemotherapy
#14
Tae Hoon Kong, Sung Min Han, Young Joon Seo
Docetaxel, derived from the yew tree, belongs to the taxane family of medications. It works by disrupting the normal function of microtubules, thereby stopping cell division. Docetaxel is used in the treatment of ovarian, breast, esophageal, gastric, prostate, lung, and head and neck cancers. Common side effects include hair loss, low blood cell counts, peripheral neuropathy, vomiting, and muscle pain. Auricular chondritis with ear deformity has not been reported previously as a side effect of docetaxel. In this paper, we present the case of a 64-year-old male patient with chondritis accompanied by ear deformity that developed due to docetaxel-carboplatin chemotherapy for non-small cell lung cancer...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29561309/acute-myositis-an-unusual-and-severe-side-effect-of-docetaxel-a-case-report-and-literature-review
#15
Philippe Rochigneux, Nicolas Schleinitz, Mikael Ebbo, Marie Aymonier, Bertrand Pourroy, Romain Boissier, Sébastien Salas, Jean-Laurent Deville
Docetaxel is an antimicrotubules cytotoxic agent prescribed widely by medical oncologists in multiple tumor types (breast, lung, prostate, stomach, head, and neck). However, the side effects of docetaxel are numerous (cytopenia, peripheral edema, myalgia, arthralgia, alopecia, and sensitive neuropathy) and recent concerns have been raised about neutropenic enterocolitis in France. Here, we report the case of a 57-year-old patient with metastatic prostatic cancer, who developed a severe myositis and fasciitis grade IV 1 week after his second docetaxel infusion...
June 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29561303/effect-of-a-complementary-integrative-medicine-treatment-program-on-taxane-induced-peripheral-neuropathy-a-brief-report
#16
Eran Ben-Arye, Yaron River, Yael Keshet, Ofer Lavie, Pesi Israeli, Noah Samuels
OBJECTIVE: Peripheral neuropathy is a common complication of cancer treatment impairing quality of life and function. This study explored the impact of a complementary and integrative medicine (CIM) program on taxane-induced peripheral neuropathy (TIPN). MATERIALS AND METHODS: Taxane-treated female patients with breast and gynecological cancer reporting TIPN-related symptoms were referred to an integrative physician, followed by patient-tailored CIM treatments (acupuncture with/without other modalities)...
June 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29546345/supplement-use-and-chemotherapy-induced-peripheral-neuropathy-in-a-cooperative-group-trial-s0221-the-delcap-study
#17
Gary R Zirpoli, Susan E McCann, Lara E Sucheston-Campbell, Dawn L Hershman, Gregory Ciupak, Warren Davis, Joseph M Unger, Halle C F Moore, James A Stewart, Claudine Isaacs, Timothy J Hobday, Muhammad Salim, Gabriel N Hortobagyi, Julie R Gralow, G Thomas Budd, Kathy S Albain, Christine B Ambrosone
Background: Chemotherapy-induced peripheral neuropathy (CIPN) can interfere with daily function and quality of life, and there are no known preventive approaches. In a cohort of breast cancer patients receiving paclitaxel as part of a clinical trial (SWOG 0221), we examined the use of dietary supplements both before diagnosis and during treatment in relation to CIPN. Methods: At registration to S0221, 1225 breast cancer patients completed questionnaires regarding the use of multivitamins and supplements before and at diagnosis...
December 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29532763/co-delivery-of-doxorubicin-and-d-%C3%AE-tocopherol-polyethylene-glycol-1000-succinate-by-magnetic-nanoparticles
#18
Esra Metin, Pelin Mutlu, Ufuk Gunduz
BACKGROUND: Although conventional chemotherapy is the most common method for cancer treatment, it has several side effects such as neuropathy, alopecia and cardiotoxicity. Since the drugs are given to body systemically, normal cells are also affected, just like cancer cells. However, in recent years, targeted drug delivery has been developed to overcome these drawbacks. OBJECTIVE: The aim in this study was targeted co-delivery of doxorubicin (Dox) which is an anticancer agent and D-α-Tocopherol polyethylene glycol 1000 succinate (vitamin E TPGS or simply TPGS) to breast cancer cells...
March 13, 2018: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29483450/-a-case-of-advanced-breast-cancer-effectively-treated-with-bevacizumab-and-letrozole
#19
Yukiko Hara, Kenichi Sakurai, Keita Adachi, Asako Fujiwara, Yoko Ono, Eiko Waga, Tomohiro Hirano, Katsuhisa Enomoto
We report a case of primary advanced breast cancer that was locally controlled by treatment with bevacizumab. A 69-yearold woman presented at our hospital complaining of left breast hemorrhage. Her left breast had a large mass with an ulcer, and there was bleeding. Breast ultrasonography showed a large tumor that involved the whole left breast, and some swollen axillary lymph nodes. Breast MRI showed a mass of 77mm and skin invasion around the medial area of the left breast. Histopathological examination indicated invasive ductal carcinoma, ER(+), PgR(+), HER2(-), Ki-67 20%...
February 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29483012/lactate-dehydrogenase-as-a-prognostic-marker-in-neoplastic-meningitis
#20
Bernardo Cacho-Díaz, Nydia A Lorenzana-Mendoza, Gervith Reyes-Soto, Allan Hernández-Estrada, Alejandro Monroy-Sosa, Paola Guraieb-Chahin, David Cantu-de-León
This study aimed to establish the prognostic utility of lactate dehydrogenase (LDH) levels in the cerebrospinal fluid (CSF) of patients with neoplastic meningitis (NM). Patients with a confirmed diagnosis of NM at a cancer referral center were included. Data on demographic and oncological background, clinical symptoms, diagnostic tests, treatment, and survival were analyzed. In total, 119 patients were included, 74% of whom were females. The mean age was 44.2 years at the time of cancer diagnosis and 46.6 years at the time between NM diagnosis...
May 2018: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
keyword
keyword
5718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"